New Zealand medicine maker AFT Pharmaceuticals says it remains on track to hit its NZ$300 million revenue target for the 2027 financial year after every division posted double-digit revenue growth in the first half.
AFT reaffirms profit guidance as its R&D pipeline moves toward 2029 launches
October 7, 2026 Latest NewsBioPharma
Latest Video
New Stories
-
The 'Dispatched' Week in Review Podcast - 6 November
November 6, 2026 - - Podcast -
Omico names laboratory partners to expand genomic profiling for Australians with cancer
November 6, 2026 - - Latest News -
Marie Guillet joins the European Australian Business Council board
November 6, 2026 - - Latest News -
The next agreements must end the culture of enforced silence
November 6, 2026 - - Latest News -
The lessons we can take from 'Robodebt' and the Reserve Bank reforms
November 6, 2026 - - Latest News -
Vaccines dominate public health spending but prevention investment slips
November 5, 2026 - - Latest News -
Increased accountability can be the only response to expanding authority
November 5, 2026 - - Latest News
